

Bronchiectasis in COPD patients: more than a comorbidity? [Corrigendum]

Martinez-Garcia MA, Miravittles M. *Int J Chron Obstruct Pulmon Dis.* 2017;12:1401–1411.

Page 1409, Disclosure, the text “The authors report no conflicts of interest in this work” should read “MM has received speaker fees from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, CSL Behring, Grifols and Novartis; consultancy fees from Boehringer Ingelheim,

Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratories Esteve, Mereo BioPharma, Verona Pharma, pH Pharma, Novartis and Grifols; and research grants from GlaxoSmithKline and Grifols. MAM has received speaker fees from Chiesi, Grifols, Novartis, TEVA and Zambon; consultancy fees from Zambon and TEVA; and research grants from Zambon”.

International Journal of COPD

Dovepress

Publish your work in this journal

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

This journal is indexed on PubMed Central, MedLine and CAS. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal>

